1.Seggewiss, R, Einsele, H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010; 115: 3861–3868.
2.Cardoso, MFS, et al. Risk factors for healthcare associated infections in patients with cancer and neutropenia and evaluation of a specific component for surveillance. American Journal of Infection Control 2007; 35: E189–E190.
3.Offer, F, et al. Mortality hazard functions as related to neutropenia at different times after marrow transplantation. Blood 1996; 88: 4058–4062.
4.Afessa, B, Peters, S. Major complications following hematopoietic stem cell transplantation. Seminars in Respiratory and Critical Care Medicine 2006; 27: 297–309.
5.Gjertson, DW, et al. Four causes of cadaveric kidney transplant failure: a competing risk analysis. American Journal of Transplantation 2002; 2: 84–93.
6.Klein, JP, et al. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: Unadjusted analysis. Bone Marrow Transplantation 2001; 28: 909–915.
7.Putter, H, Fiocco, M, Geskus, R. Tutorial in biostatistics: competing risks and multi-state models. Statistics in Medicine 2007; 26: 2277–2432.
8.Prentice, RL, et al. The analysis of failure times in the presence of competing risks. Biometrics 1978; 34: 541–554.
9.Koller, MT, et al. Meta-analyses of chronic disease trials with competing causes of death may yield biased odds ratios. Journal of Clinical Epidemiology 2008; 61: 365–372.
10.Dettenkofer, M, et al. Surveillance of nosocomial sepsis and pneumonia in patients with a bone marrow or peripheral blood stem cell transplant: a multicenter project. Clinical Infectious Diseases 2005; 40: 926–931.
11.Johnson, LE, et al. Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcome in transplant recipients. Transplant Infectious Disease 2009; 11: 227–234.
12.Moreno, A, et al. Bloodstream infections among transplant recipients: results of a nationwide surveillance in Spain. American Journal of Transplantation 2007; 7: 2579–2586.
13.Worth, LJ, Salvin, MA. Bloodstream infections in haematology risks and new challenges for prevention. Blood Reviews 2009; 2: 113–122.
14.Meyer, E, et al. Risk factor analysis of blood stream infection and pneumonia in neutropenic patients after peripheral blood stem-cell transplantation. Bone Marrow Transplant 2007; 39: 173–178.
15.Fine, J, Gray, RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association 1999; 94: 496–509.
16.Beyersmann, J, et al. A competing risks analysis of bloodstream infection after stem-cell transplantation using subdistribution hazards and cause-specific hazards. Statistics in Medicine 2007; 26: 5360–5369.
17.Lin, DY. Non-parametric inference for cumulative incidence functions in competing risks studies. Statistics in Medicine 1997; 16: 901–910.
18.Lagakos, SW. Time-to-event analyses for long-term treatments – the APPROVe trial. New England Journal of Medicine 2006; 355: 113–117.
19.Klein, JP, et al. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part II: Regression modelling. Bone Marrow Transplantation 2001; 28: 1001–1011.
20.Bailey, RC, Lin, M, Krakauer, H. Time-to-event modeling of competing risks with intervening states in transplantation. American Journal of Transplantation 2003; 3: 192–202.
21.Aalen, O, Johansen, S. An empirical transition matrix for non-homogeneous Markov chains based on censored observations. Scandinavian Journal of Statistics 1978; 5: 141–150.
22.Andersen, PK, et al. Statistical Models Based on Counting Processes. Springer Series in Statistics. New York, NY: Springer, 1993.
23.Schulgen, G, et al. Sample sizes for clinical trials with time-to-event endpoints and competing risks. Contemporary Clinical Trials 2005; 26: 386–395.
24.Latouche, A, Porcher, R. Sample size calculations in the presence of competing risks. Statistics in Medicine 2007; 26: 5370–5380.